文献速递临床试验与 GCP

微创玻璃体切割联合内界膜剥除对比抗VEGF玻璃体腔注射治疗初治糖尿病黄斑水肿(VVV-DME研究):随机对照试验研究方案

Microinvasive pars plana vitrectomy combined with internal limiting membrane peeling versus anti-VEGF intravitreal injection for treatment-naïve diabetic macular edema (VVV-DME study): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-10-24

本研究为单中心、前瞻性、平行组、非劣效性随机对照试验,纳入102例初治糖尿病黄斑水肿患者,按1:1随机分配至玻璃体切割联合内界膜剥除组或康柏西普玻璃体腔注射组,术后随访12个月。主要结局为中心子区域厚度和黄斑区最佳矫正视力的变化,旨在探讨早期玻璃体切割联合内界膜剥除能否减轻治疗负担并维持糖尿病视网膜病变长期稳定。

要点

  • 纳入102例初治糖尿病黄斑水肿患者,随机分为玻璃体切割联合内界膜剥除组与康柏西普注射组。
  • 主要结局为中央子区域厚度和最佳矫正视力变化,随访至术后12个月。
  • 旨在评估早期玻璃体切割联合内界膜剥除能否成为初治糖尿病黄斑水肿的初始治疗选择。

核心结论

  • VVV研究旨在探讨玻璃体切割联合内界膜剥除能否成为初治糖尿病黄斑水肿患者的初始治疗选择。

研究设计与样本

  • 单中心、前瞻性、平行组、非劣效性随机对照试验,纳入102例糖尿病黄斑水肿参与者。
  • 参与者按1:1随机分配至研究组(玻璃体切割联合内界膜剥除)或对照组(康柏西普玻璃体腔注射),计划术后随访12个月。
  • 于干预后第1、3、6、12个月对两组结果进行比较分析。
  • 主要结局为中央子区域厚度和最佳矫正视力的变化。
  • 次要结局包括光学相干断层扫描(OCT)和OCT血管成像(OCTA)生物标志物、再治疗率与不良事件率、糖尿病视网膜病变进展、成本效果分析及视觉相关生活质量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diabetic macular edema (DME) is the main cause of vision loss in diabetic patients. Currently, anti-vascular endothelial growth factor (VEGF) intravitreal injection stands as the first-line therapy for DME. However, some patients exhibit insufficient response to anti-VEGF agents and often require multiple injections, imposing psychological and economic burdens. While microinvasive pars plana vitrectomy (PPV) has been shown to be safe and effective in treating refractory DME, scant research has explored its application to treatment-naïve DME. The purpose of this study is to determine whether early PPV combined with internal limiting membrane (ILM) peeling can lessen the therapeutic burden of DME patients, prevent vision loss, and maintain long-term stabilization of diabetic retinopathy. METHODS: This is a single-center, prospective, parallel-group, non-inferiority randomized controlled trial involving 102 DME participants. Participants will be randomly assigned to either the study group (PPV combined with ILM peeling) or the control group (conbercept intravitreal injection (IVC)) at a 1:1 ratio, with a scheduled follow-up at 12 months post-operation. Comparative analysis of results between the two groups will be conducted at months 1, 3, 6, and 12 after the intervention. The primary outcomes involve evaluating the changes in central subfield thickness (CST) and best corrected visual acuity (BCVA). The secondary outcomes include assessment of optical coherence tomography (OCT) and OCT angiography (OCTA) biomarkers, re-treatment and adverse events rates, diabetic retinopathy (DR) development, cost-effectiveness analysis, and vision-related quality of life (VRQL). DISCUSSION: Some patients do not respond well to anti-VEGF drugs and repeated intravitreal injections increase the treatment burden for patients. The VVV study aims to explore whether PPV combined with ILM peeling could become an initial treatment option for treatment-naïve DME patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT05728476. Registered on 15 February 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Guo H, Li W, Nie Z, et al. Microinvasive pars plana vitrectomy combined with internal limiting membrane peeling versus anti-VEGF intravitreal injection for treatment-naïve diabetic macular edema (VVV-DME study): study protocol for a randomized controlled trial. Trials. 2023. PMID: 37875997. doi:10.1186/s13063-023-07735-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。